Radiometals for Combined Imaging and Therapy

被引:320
作者
Cutler, Cathy S. [1 ]
Hennkens, Heather M. [1 ]
Sisay, Nebiat [1 ,2 ]
Huclier-Markai, Sandrine [3 ]
Jurisson, Silvia S. [2 ]
机构
[1] Univ Missouri, Res Reactor Ctr, Columbia, MO 65211 USA
[2] Univ Missouri, Dept Chem, Columbia, MO 65211 USA
[3] Univ Nantes, Lab Subatech, UMR 6457, Ecole Mines Nantes,CNRS IN2P3, F-44307 Nantes 3, France
关键词
POSITRON EMISSION TOMOGRAPHY; METASTATIC BONE PAIN; COPPER-64-LABELED MONOCLONAL-ANTIBODY; PARTICLE-EMITTING RADIONUCLIDES; CLUSTER-LABELED ANTIBODIES; NUCLEAR-MEDICINE THERAPY; RAY CRYSTAL-STRUCTURES; DOTA-BINDING ANTIBODY; SCHIFF-BASE COMPLEXES; IN-VIVO EVALUATION;
D O I
10.1021/cr3003104
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A study was conducted to demonstrate the use of radiometals for combined imaging and therapy. The study presented radiometals that had the nuclear properties required for use in theranostic applications for imaging and therapy. Their chemistry and production methods were discussed, along with examples of preclinical and clinical uses. A number of radiometals had been evaluated for positron emission tomography (PET) due to their favorable nuclear properties. The choice of type and energy of the particle emission was determined by the size of the lesion or tumor being treated, site of delivery, whether the tumor was homogeneous, and whether the dose was delivered uniformly to each cell. A major advantage of using such nanosized radioactive particles was their potential to contain numerous radioactive atoms within a single nanoparticle.
引用
收藏
页码:858 / 883
页数:26
相关论文
共 213 条
[41]   Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: Ligand generality from a chiral system [J].
Corneillie, TM ;
Fisher, AJ ;
Meares, CF .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (49) :15039-15048
[42]  
Cotton S., 2006, INORG CHEM
[43]   Cancer radioimmunotherapy with alpha-emitting nuclides [J].
Couturier, O ;
Supiot, S ;
Degraef-Mougin, M ;
Faivre-Chauvet, A ;
Carlier, T ;
Chatal, JF ;
Davodeau, F ;
Cherel, M .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (05) :601-614
[44]  
Cutler CS, 2009, J LABELLED COMPD RAD, V52, pS96
[45]   Current and potential therapeutic uses of lanthanide radioisotopes [J].
Cutler, CS ;
Smith, CJ ;
Ehrhardt, GJ ;
Tyler, TT ;
Jurisson, SS ;
Deutsch, E .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (06) :531-545
[46]  
CUTLER PD, 1995, J NUCL MED, V36, P2363
[47]   Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody [J].
Dearling, Jason L. J. ;
Voss, Stephan D. ;
Dunning, Patricia ;
Snay, Erin ;
Fahey, Frederic ;
Smith, Suzanne V. ;
Huston, James S. ;
Meares, Claude F. ;
Treves, S. Ted ;
Packard, Alan B. .
NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (01) :29-38
[48]   Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships [J].
Dearling, JLJ ;
Lewis, JS ;
Muller, GED ;
Welch, MJ ;
Blower, PJ .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2002, 7 (03) :249-259
[49]   EVALUATION IN-VITRO AND IN RATS OF TB-161-DTPA-OCTREOTIDE, A SOMATOSTATIN ANALOG WITH POTENTIAL FOR INTRAOPERATIVE SCANNING AND RADIOTHERAPY [J].
DEJONG, M ;
BREEMAN, WAP ;
BERNARD, BF ;
ROLLEMAN, EJ ;
HOFLAND, LJ ;
VISSER, TJ ;
SETYONOHAN, B ;
BAKKER, WH ;
VANDERPLUIJM, ME ;
KRENNING, EP .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1995, 22 (07) :608-616
[50]  
Delpassand E. S., 2008, CANCER BIOTHER RADI, P23